Highest development stage: Phase 1

Development status: Inactive

Gram-negative activity

Mechanism of Action/Target pathogen: Use against Endocarditis infections

Reason dropped: This was probably one of a long series of oxazolidinones from Pharmacia - not followed up on by Pfizer. Likely no signficant improvement over linezolid. Lots of companies worked on oxazolidinones after Pharmacia/Pfizer registered linezolid. There are some toxicities that it has been hard to overcome. A newer oxazolidinone [tadezolid] may have some potency improvements over linezolid [and activity against some linezolid resistant bugs, which are not prevalent]- (LS)